Does a patient with severe mitral regurgitation (MR) require anticoagulation therapy?

Anticoagulation in Severe Mitral Regurgitation

Severe mitral regurgitation alone does NOT require anticoagulation in patients who remain in normal sinus rhythm. 1, 2

Primary Indication: Atrial Fibrillation

The decision to anticoagulate hinges entirely on whether atrial fibrillation is present, not on the severity of mitral regurgitation itself:

• Anticoagulation is mandatory when atrial fibrillation develops (permanent or paroxysmal), with a target INR of 2.0-3.0 using warfarin or vitamin K antagonists 1, 2
• Direct oral anticoagulants (DOACs) can be used in mitral regurgitation with atrial fibrillation, as they are NOT contraindicated (unlike in mitral stenosis) 1
• Recent research suggests DOACs may offer comparable or superior outcomes to warfarin in this population 3

Secondary Indications for Anticoagulation

Anticoagulation (INR 2.0-3.0) is indicated in severe mitral regurgitation patients who have: 1, 2

• History of systemic embolism
• Evidence of left atrial thrombus on echocardiography
• Dense spontaneous echocardiographic contrast in the left atrium

Post-Surgical Anticoagulation

Following mitral valve repair, anticoagulation is required for the first 3 months only (INR 2.0-3.0), then discontinued if sinus rhythm is maintained 1, 2

For mechanical mitral valve replacement:

• Warfarin with target INR 2.5-3.5 plus aspirin 75-100 mg daily indefinitely 1, 2

For bioprosthetic mitral valve replacement:

• Warfarin for first 3 months (INR 2.0-3.0), then aspirin alone if no atrial fibrillation 1, 2

Critical Distinction: Mitral Regurgitation vs. Mitral Stenosis

This is fundamentally different from mitral stenosis, where anticoagulation is often indicated even in sinus rhythm due to high thromboembolic risk 2, 4. Prospective trials have not demonstrated benefit of antithrombotic therapy for stroke prevention in mitral regurgitation patients without atrial fibrillation 1, 2.

Common Pitfalls to Avoid

• Do not anticoagulate based on severity of regurgitation alone - this is a common error stemming from confusion with mitral stenosis management 2
• Do not use NOACs in patients with moderate-to-severe mitral stenosis (if coexistent), as they are contraindicated 1
• Do not delay anticoagulation once atrial fibrillation develops, as maintenance of sinus rhythm after cardioversion is unlikely unless the mitral regurgitation is surgically corrected 1

Management Algorithm

1. Assess rhythm: Sinus rhythm vs. atrial fibrillation
2. If sinus rhythm: No anticoagulation unless history of embolism or left atrial thrombus 1, 2
3. If atrial fibrillation: Initiate anticoagulation (warfarin INR 2.0-3.0 or DOAC) 1, 2
4. Post-valve repair: 3 months anticoagulation, then reassess based on rhythm 1, 2